FDA Expands Pemetrexed Approval for Frontline PembrolizumabChemo Combo in NSCLC

FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.

More From BioPortfolio on "FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC"